Zimmer Biomet Holdings, Inc. (ZBH) Upgraded by Deutsche Bank AG to “Buy”

Deutsche Bank AG upgraded shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) from a hold rating to a buy rating in a research report released on Tuesday morning. The firm currently has $128.00 target price on the medical equipment provider’s stock.

ZBH has been the topic of a number of other reports. Morgan Stanley increased their target price on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an overweight rating in a report on Monday, July 17th. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a hold rating to a sell rating in a report on Tuesday, August 1st. BidaskClub lowered shares of Zimmer Biomet Holdings from a buy rating to a hold rating in a report on Monday, July 24th. Canaccord Genuity lowered shares of Zimmer Biomet Holdings from a buy rating to a hold rating and reduced their target price for the stock from $141.00 to $135.00 in a report on Friday, July 28th. Finally, Piper Jaffray Companies reiterated a buy rating and set a $135.00 target price on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Hold and an average target price of $133.71.

Zimmer Biomet Holdings (NYSE ZBH) opened at $111.61 on Tuesday. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. Zimmer Biomet Holdings has a fifty-two week low of $98.20 and a fifty-two week high of $133.49. The company has a market cap of $22,730.00, a P/E ratio of 13.90, a PEG ratio of 1.74 and a beta of 1.17.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. During the same quarter in the prior year, the company posted $1.79 earnings per share. The business’s revenue was down .8% compared to the same quarter last year. research analysts anticipate that Zimmer Biomet Holdings will post 8.03 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Upgraded by Deutsche Bank AG to “Buy”” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://baseballnewssource.com/markets/zimmer-biomet-holdings-inc-zbh-upgraded-by-deutsche-bank-ag-to-buy/1782740.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Iguana Healthcare Management LLC grew its position in shares of Zimmer Biomet Holdings by 20.0% in the 3rd quarter. Iguana Healthcare Management LLC now owns 30,000 shares of the medical equipment provider’s stock valued at $3,513,000 after buying an additional 5,000 shares during the last quarter. Belpointe Asset Management LLC purchased a new position in shares of Zimmer Biomet Holdings in the 3rd quarter valued at $1,600,000. IFM Investors Pty Ltd purchased a new position in shares of Zimmer Biomet Holdings in the 3rd quarter valued at $656,000. Afam Capital Inc. grew its position in shares of Zimmer Biomet Holdings by 3.8% in the 3rd quarter. Afam Capital Inc. now owns 46,108 shares of the medical equipment provider’s stock valued at $5,399,000 after buying an additional 1,679 shares during the last quarter. Finally, Highlander Capital Management LLC grew its position in shares of Zimmer Biomet Holdings by 22.0% in the 3rd quarter. Highlander Capital Management LLC now owns 3,324 shares of the medical equipment provider’s stock valued at $389,000 after buying an additional 600 shares during the last quarter. 85.44% of the stock is currently owned by hedge funds and other institutional investors.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.